Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Hims & Hers Health reported quarterly earnings of $0.17 per share, meeting analyst expectations, with a net margin of 9.24% and a return on equity of 22.75%.
• Shares of Hims & Hers Health increased by 1.3% to $63.38, supported by significant trading volume of over 35 million shares.
• Despite the positive earnings report, analysts maintain a mixed outlook, with an average rating of "Hold" and a target price of $39.83 for the stock.

Hims & Hers Health (NYSE:HIMS - Get Free Report) released its quarterly earnings results on Monday. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01), Zacks reports. The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 27.26%. The company's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 earnings per share. Hims & Hers Health updated its Q3 2025 guidance to EPS and its FY 2025 guidance to EPS.

Hims & Hers Health Trading Down 8.4%

Shares of Hims & Hers Health stock traded down $4.66 during trading on Wednesday, hitting $50.86. 36,880,440 shares of the stock traded hands, compared to its average volume of 34,376,496. The firm has a market cap of $11.38 billion, a P/E ratio of 63.59, a price-to-earnings-growth ratio of 2.34 and a beta of 2.08. Hims & Hers Health has a 52-week low of $13.47 and a 52-week high of $72.98. The stock's fifty day simple moving average is $53.83 and its 200 day simple moving average is $44.59.

Analysts Set New Price Targets

HIMS has been the subject of a number of recent research reports. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Piper Sandler restated a "neutral" rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. UBS Group set a $30.00 price objective on Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday. Finally, TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and cut their price objective for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $39.83.

Insider Activity

In related news, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52. Following the completion of the transaction, the chief executive officer directly owned 160,215 shares in the company, valued at approximately $9,093,803.40. This trade represents a 44.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of the business's stock in a transaction that occurred on Monday, June 23rd. The shares were sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the sale, the chief financial officer owned 63,222 shares of the company's stock, valued at $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 737,704 shares of company stock worth $40,644,035. Company insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

A hedge fund recently bought a new stake in Hims & Hers Health stock. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,018 shares of the company's stock, valued at approximately $30,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.